Clinical Study On Xuezhikang Capsule In The Treatment Of Dyslipidemia In Different Syndromes Of Traditional Chinese Medicine

AIMS:The aims of this study are to determine the effect of Xuezhikang capsule and to investigate the therapeutical effect in different TCM syndromes of dyslipidemia.METHODS:A total of60patients, treated at the Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, in the period from June2010to May2011, and with a hospital discharge diagnosis of dyslipidemia, were induced. According to randomized, doubled-blind, placebo-controlled principle,60patients were divided into the treatment group (45) and control group (15). Patients in the treatment group were segmented into five small groups on the basis of TCM syndromes:sputum stasis syndrome, spleen-yang deficiency and kidney-yang deficiency syndrome, hepatic and renal yin deficiency syndrome, yin deficiency and yang excessive syndrome and qi-stagnation induced blood-stasis syndrome group.Patients in treatment group were given Xuezhikang-capsules, while the counterparts in the control group were given placebos. The period of treatment was8weeks, and a2-week telephone interview was also included. Changes of triglyceride (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and TCM symptoms were observed. Security indexes:ALT (alannine aminotransferase), AST (aspartate aminotransferase), BUN (blood urea nitrogen), CRE (creatinine) and CK (creatine kinase) were recorded before and after the treatment.RESULTS:1. After8wekks, Xuezhikang-capsule had significant functions on lowing TG and LDL-C and improving TCM syndromes. Therapeutic effect of thetreatment group was superior to that in the control group (P<0.05). No significant difference was found in the security indexes during the whole treatment period (P>0.05)2. In the treatment group. TC in the sputum stasis syndrome group and hepatic and renal yin deficiency syndrome group had been largely lowed (P<0.05).however, there was no significant statistical difference between the above two groups. The variation of TC in all the rest three TCM syndrome groups. had no significant difference after treatment (P<0.05). LDL-C had been dramatically decreased in the sputum stasis syndrome group only (P<0.05). TG and HDL-C in the five TCM syndrome groups had no statistical difference in the treatment period (P>0.05)3. Researchers of this study founded that Xuezhikang-capsule could ameliorate85.37%of the selected41clinical symptoms. Hepatic and renal yin deficiency syndrome group had the best therapeutical effect, which can improve82.87%TCM symptoms. Sputum stasis syndrome group ranked the second in the five groups with the ratio of82.50%, and qi-stagnation induced blood-stasis syndrome group had the lowest therapeutical-effect ratio of31.03%.CONCLUSIONS:It was found in this study that Xuezhikang-capsule could regulate the TC and LDL-C levels efficiently and safely. Moreover, it could improve the TCM symptoms obviously and the therapeutical-effect differentiation of diverse TCM syndrome types had existed.